• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 6, 2017

View Archived Issues

Gurnet Point offers $55M cash, $154M CVR for Innocoll

DUBLIN – Shares in Innocoll Holdings plc surged by more than 86 percent during pre-market trading on Nasdaq Wednesday on news of a takeover offer from Gurnet Point LP valued at up to $209 million. Read More

Cancer has another hallmark moment

WASHINGTON – “Hallmarks and enabling characteristics should be not special cases, but rather reasonably broad across the spectrum of human cancers,” Robert Weinberg told BioWorld Today. Read More

Time to shine, Intezyne: Nanoparticle enters clinic, GRP78 work marching on

Intezyne Technologies Inc. should find itself “on an IPO trajectory for late 2018 or early 2019,” its chief financial officer (CFO), Russell McAllister, told BioWorld Today, “coinciding with potential licensing deals for both” lead candidates owned by the Tampa, Fla.-based company. Read More

CFDA clears JHL’s IND for studies of Rituximab biosimilar

HONG KONG – The CFDA recently accepted a clinical trial application (CTA) to conduct phase I and phase III trials of rituximab biosimilar JHL1101, submitted by JHL Biotech Inc., a startup based in Zhubei City, Taiwan, and Wuhan, China. If successful, the biosimilar will be key to improving drug access in the country for patients with non-Hodgkin’s lymphoma (NHL). Read More

Financings

Ohr Pharmaceutical Inc., of New York, said it priced a registered public offering at 70 cents per share of common stock and accompanying warrant to purchase 0.7 of a share of common stock at an exercise price of $1 per share. Read More

Appointments and advancements

Alexion Pharmaceuticals Inc., of New Haven, Conn., named Ludwig Hantson CEO. Read More

Other news to note

Therapix Biosciences Ltd., of Tel Aviv, Israel, said Yissum Research Development Co. will grant it an exclusive, worldwide, sublicensable, royalty-bearing license to its technology for the nasal delivery of cannabinoids. Read More

AACR 2017

Bio-path Holdings Inc., of Houston, said its second product candidate, a neutral-charge, liposome-incorporated antisense drug called BP1002, was shown to have strong anti-non-Hodgkin’s lymphoma activity in preclinical in vitro and in vivo studies. Read More

In the clinic

Saniona AB, of Ballerup, Denmark, said it started a phase IIa study in the Czech Republic and Hungary for Tesomet in patients with Prader-Willi syndrome (PWS), having randomized the first three patients to either receive the drug, a combination of tesofensine 0.5 mg plus metoprolol 50 mg daily, or placebo. Read More

Regulatory front

Reminding President Donald Trump of his promises to bring down drug prices, 51 members of Congress signed a letter to the president Tuesday urging him to direct the NIH to issue guidance on circumstances that could cause it to exercise its march-in rights on patents based on research it funded. Read More

Zavante looks for piece of antibiotics action as Zolyd hits in cUTI

Privately held Zavante Therapeutics Inc. hopes to push the antibiotics envelope a bit further after its single agent, Zolyd (fosfomycin for injection, previously ZTI-01), met the primary endpoint of statistical noninferiority to piperacillin/tazobactam (Zosyn, Pfizer Inc.) at the highest approved dose in the pivotal phase II/III ZEUS trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe